

Nectar Lifesciences UK Limited

Annual Report and Unaudited Financial Statements

For the year ended 31 March 2022

Nectar Lifesciences UK Limited

Company Information

Directors	Dr D Dua Nectar Lifesciences Limited
Company number	07547409
Registered office	Devonshire House 60 Goswell Road London EC1M 7AD
Accountants	Moore Kingston Smith LLP Betchworth House 57-65 Station Road Redhill Surrey RH1 1DL

Nectar Lifesciences UK Limited

Directors' Report

For the year ended 31 March 2022

The directors present their annual report and financial statements for the year ended 31 March 2022.

Principal activities

The company is dormant and has not traded during the year.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr D Dua
Nectar Lifesciences Limited

Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board

DINESH
DUA

Digitally signed
by DINESH DUA
Date: 2022.05.20
19:13:23 +05'30'

Dr D Dua
Director

Date: 20-05-2022

Nectar Lifesciences UK Limited

Balance Sheet

As at 31 March 2022

	Notes	2022 £	£	2021 £	£
Current assets					
Debtors	3	1		1	
		<u> </u>		<u> </u>	
Net current assets			1		1
			<u> </u>		<u> </u>
Capital and reserves					
Called up share capital	4		1		1
			<u> </u>		<u> </u>

For the financial year ended 31 March 2022 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 20-05-2022 and are signed on its behalf by:

DINESH
DUA

Dr D Dua
Director

Digitally signed by
DINESH DUA
Date: 2022.05.20
19:13:53 +05'30'

Company Registration No. 07547409

Nectar Lifesciences UK Limited

Notes to the Financial Statements

For the year ended 31 March 2022

1 Accounting policies

Company information

Nectar Lifesciences UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is Devonshire House, 60 Goswell Road, London, EC1M 7AD.

1.1 Accounting convention

These financial statements have been prepared in accordance with Section 1A of FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Profit and loss account

The company has not traded during the year or the preceding financial period. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

1.3 Financial instruments

The company only has financial instruments classified as basic and measured at amortised cost. The company has no financial instruments that are classified as 'other' or financial instruments measured at fair value.

1.4 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2 Employees

The average monthly number of persons (including directors) employed by the company during the year was:

	2022 Number	2021 Number
	1	1
	=====	=====
3 Debtors	2022	2021
Amounts falling due within one year:	£	£
Amounts owed by group undertakings	1	1
	=====	=====

Nectar Lifesciences UK Limited

Notes to the Financial Statements (Continued)

For the year ended 31 March 2022

4 Called up share capital

	2022 £	2021 £
Ordinary share capital		
Issued and fully paid		
1 Ordinary share of £1	1	1
	<u> </u>	<u> </u>

5 Parent company

The parent company is Nectar Lifesciences Limited, a company registered in India, by virtue of its' 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Disst. S.A.S. Nagar (Mohali) Punjab, India.

DINESH
DUA

Digitally signed by
DINESH DUA
Date: 2022.05.20
19:14:11 +05'30'

Nectar Lifesciences USA LLC

Directors' Report For the year ended 31 March 2022

The directors present their annual report and financial statements for the year ended 31 March 2022.

Principal activities

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption. During the year under review the Company has incurred the loss of USD 37914.00 as against the loss of USD 10096.00 last year.

Audit

Nectar Lifesciences US, LLC, being a privately held company, is not required to get its financial statement audited for the financial year ended on March 31, 2022 under any law of the US.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Sanjiv Goyal
Nectar Lifesciences Limited

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

For Nectar Lifesciences USA LLC

SANJIV
GOYAL

Digitally signed by
SANJIV GOYAL
Date: 2022.05.19
19:15:58 +05'30'

(Sanjiv Goyal)

Operating Manager/ Director

Dated: 19.05.2022

Nectar Lifesciences USA LLC

Balance Sheet As At 31st March 2022

Particulars	NOTE	31-Mar-22	31-Mar-21
<u>EQUITY AND LIABILITIES</u>		USD	USD
Share holders' Fund			
Share Capital		\$51,950.00	\$51,950.00
Reserves & Surplus	2.01	\$80,547.39	\$1,18,461.39
Current Liabilities			
Trade Payables	2.02	-	\$72,753.61
Other Current Liabilities	2.03	\$11,110.00	-
Total		\$1,43,607.39	\$2,43,165.00
<u>ASSETS</u>			
Current Assets			
Inventories	2.04	\$11,200.00	\$1,25,200.00
Trade Receivables	2.05	-	\$1,04,757.00
Other Current Assets	2.06	\$1,24,320.39	-
Cash & Bank Balances	2.07	\$8,087.00	\$13,208.00
		\$1,43,607.39	\$2,43,165.00

Nectar Lifesciences USA LLC

Statement of Profit and Loss For the year ended 31st March 2022

Particulars	NOTE	31-Mar-22	31-Mar-21
INCOME		USD	USD
Revenue From Operations	2.08	\$81,225.00	\$1,97,870.00
		\$81,225.00	\$1,97,870.00
EXPENDITURE			
Purchase of Stock in Trade		-	-
Changes in Inventories of Stock in Trade	2.09	\$1,14,000.00	\$1,95,300.00
Other Expenses	2.10	\$5,139.00	\$12,666.00
		\$1,19,139.00	\$2,07,966.00
PROFIT (LOSS) BEFORE TAX		(\$37,914.00)	(\$10,096.00)

Nectar Lifesciences USA LLC

Particulars	31-Mar-22 USD	31-Mar-21 USD
NOTE - 2.01 "RESERVES & SURPLUS"		
Surplus in Statement of Profit & Loss		
Opening Balance	\$1,18,461.39	\$1,43,146.39
Transferred From Statement of Profit & Loss	(\$37,914.00)	(\$10,096.00)
	\$80,547.39	\$1,33,050.39
Appropriations :		
Corporation Business Tax	-	\$14,589.00
Total "A"	\$80,547.39	\$1,18,461.39
NOTE - 2.02 "TRADE PAYABLES"		
Trade Payables	-	\$72,753.61
	-	\$72,753.61
NOTE - 2.03 "OTHER CURRENT LIABILITIES"		
Advance recd. from customers	\$11,110.00	-
	\$11,110.00	-

Nectar Lifesciences USA LLC

Particulars	31-Mar-22 USD	31-Mar-21 USD
NOTE - 2.04 "INVENTORIES"		
(As Certified by The Management)		
Finished Goods	\$11,200.00	\$1,25,200.00
	\$11,200.00	\$1,25,200.00

NOTE - 2.05 "TRADE RECEIVABLES"		
Unsecured		
Considered Good	-	\$1,04,757.00
Considered Doubtful	-	-
	-	\$1,04,757.00
Provision For Doubtful Debts	-	-
	-	\$1,04,757.00

NOTE - 2.06 "OTHER CURRENT ASSETS"		
Advance to Suppliers	\$1,24,320.39	-
	\$1,24,320.39	-

NOTE - 2.07 "CASH & BANK BALANCES"		
Balance With Banks		
In Current Accounts	\$8,087.00	\$13,208.00
	\$8,087.00	\$13,208.00

Nectar Lifesciences USA LLC

Particulars	31-Mar-22 USD	31-Mar-21 USD
NOTE - 2.08 "REVENUE FROM OPERATIONS"		
Sale from Operations	\$81,225.00	\$1,97,870.00
	\$81,225.00	\$1,97,870.00
NOTE - 2.09 "CHANGE IN STOCK IN TRADE"		
Inventory (At Close)	\$11,200.00	\$1,25,200.00
Inventory (At Commencement)	\$1,25,200.00	\$3,20,500.00
Change	\$1,14,000.00	\$1,95,300.00
NOTE - 2.10 "OTHER EXPENSES"		
Administrative & Selling Expenses		
Freight Charges	-	\$4,086.00
Professional Charges	\$5,101.00	\$8,250.00
Bank Charges & Commission	\$38.00	\$330.00
	\$5,139.00	\$12,666.00

Nectar Lifesciences USA LLC

Notes to the Financial
Statements For the year
ended March 31, 2022

1. Accounting Policies

1.1. Accounting Conventions

The financial statements are prepared under the cost convention and in accordance with the financial reporting standard for smaller entities.

2. Control

The immediate controlling party is Nectar Lifesciences Limited, a company registered in India, by virtue of its 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Distt: S.A.S. Nagar (Mohali) Punjab, India.

3. Balance Sheet and Profit and Loss Accounts

Balance Sheet and Profit and Loss Accounts and attached with reports and entries contained there are self-explanatory.

4. Audit

Nectar Lifesciences US, LLC, being a privately held company, is not required to get its financial statement audited for the financial year ended on March 31, 2022 under any law of the US.

For **Nectar Lifesciences USA, LLC**

SANJIV GOYAL Digitally signed by SANJIV
GOYAL
Date: 2022.05.19 19:16:30 +05'30'

(Sanjiv Goyal)

Operating Manager/ Director

Dated: 19.05.2022

Neclife PT, Unipessoal LDA – Portugal

Directors' Report

For the year ended 31 March 2022

The directors present their annual report and financial statements for the year ended 31 March 2022.

Principal activities

The company has not traded during the year.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr Dinesh Dua

Nectar Lifesciences Limited

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Audit

Neclife PT, Unipessoal LDA, being a privately held company, is not required to get its financial statement audited for the financial year ended on March 31, 2022 under any law of the Portugal.

For **Neclife PT, Unipessoal LDA**

DINESH DUA Digitally signed by DINESH DUA
Date: 2022.05.19 19:24:44
+05'30'

Date: 19-05-2022

(Dr. Dinesh Dua)

Manager/ Director

Neclife PT, Unipessoal LDA – Portugal
Balance Sheet as at March 31, 2022

Assets	Note	31-Mar-22	31-Mar-21
Cash & Cash Equivalents Cash & Bank Balances	3	€ 1,000	€ 1,000
Total		€ 1,000	€ 1,000
Liabilities Shareholder's Fund Share Capital	4	€ 1,000	€ 1,000
Total		€ 1,000	€ 1,000

Neclife PT, Unipessoal LDA – Portugal

Notes to Financial Statements

For the year ended March 31, 2022

1. Accounting Policies

1.1 Accounting Conventions

The financial statements are prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The financial statements are prepared in Euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest euro.

1.2 Profit & Loss Account

The company has not traded during the year. During this time the company received no income and incurred no expenditure and therefore no profit & loss account is presented in these financial statements.

1.3 Equity Instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable (if any) on equity instruments are recognized as liabilities once they are no longer at the discretion of the company.

2. Parent Company

The parent company is Nectar Lifesciences Limited, a company registered in India, by the virtue of its 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali), Punjab, India.

Neclife PT, Unipessoal LDA – Portugal		
Cash & Cash Equivalents	Note - 3	

Particulars	31-Mar-22	31-Mar-21
Cash & Bank Balance	€ 1,000	€ 1,000
Total	€ 1,000	€ 1,000

Share Capital		
Note - 4		

Particulars	31-Mar-22	31-Mar-21
Issued and paid up share capital	€ 1,000	€ 1,000
Total	€ 1,000	€ 1,000

For **Neclife PT, Unipessoal LDA**

DINESH
DUA

Digitally signed by
 DINESH DUA
 Date: 2022.05.19
 19:25:06 +05'30'

(Dr. Dinesh Dua)

Manager/ Director

Date: 19-05-2022